Is the Invitae BRCA1 and BRCA2 STAT panel the right test for you?
This is one of a number of tests we offer which analyses the specific genes – BRCA1 and BRCA2 – associated with increased risk of developing common cancers: breast, melanoma, pancreatic, prostate and ovarian.
If you have already been diagnosed with cancer, this test is a rapid analysis that can help you make vital decisions about your treatment – particularly if you are considering surgical options.
You can get this test in a number of ways:
- Buy it directly from this website (this cost may be covered by your medical insurance).
- Access through your private healthcare provider.
This test is only available to those aged 18 years or above.
Ask your clinician how you can get this test, or download this leaflet to give to them.
Our price £595 (RRP £995) Save £400
Got a box? Enter your serial number in the box below. It is located on the reverse of the kit and consist of 14 numbers.
If you need any assistance, please call +44 (0) 1270 623 179.
- Why?►Close tab
Helping you make decisions
All of us have a 1 in 2 lifetime risk of developing cancer, but some – breast, melanoma, pancreatic, prostate and ovarian – are known to occur more frequently in families, passing from one generation to the next.
When certain inherited gene mutations are present in your DNA, it highlights not only that you have a higher than average risk of developing these cancers – but if you have already been diagnosed, it can indicate whether your cancer is more likely to recur after treatment, or if you are at greater than average risk of developing other cancers subsequently.
The key aspect of this test is speed: results are guaranteed within 5-12 calendar days (7 days on average) of your sample being received in the laboratory.
If you need to make urgent decisions about treatment – perhaps in the case of breast cancer whether to have a lump removed or a full or partial mastectomy – this test can give you and your clinician the vital knowledge to make an informed decision quickly.
For your family
It’s also important to share the test analysis with your family: because this test is about genetically inherited mutations, there could be implications for them too. For example, if a man or woman carries a mutation in BRCA1, each of their parents (mother and father), siblings (brothers and sisters) and children (sons and daughters) have a 50% chance of carrying the same mutation. Knowing if this gene mutation is in the family means everyone can ensure they receive regular monitoring and screening.
- How?►Close tab
What do I have to do?
It’s a simple ‘spit test’ that you can do in your own home – we don’t need a blood sample, all we need is your saliva. You’ll receive a kit in the post with clear instructions on giving your sample together with all the paperwork you need to sign, which you then post back to us.
- Process►Close tab
Buying the test
Step 1: There are two options:
- Via your treating hospital/private healthcare provider (we have special arrangements with many healthcare providers to enable you to access this test, click here to see the list)
- By clicking the ‘Buy direct now’ button above (the cost may be covered by your medical insurance – check your policy details)
Step 2: Collection of sample
We will liaise directly with your clinician and organise the collection of your sample and delivery to the laboratory.
Step 3: Analysis and reporting
Your sample will be analysed and a report will be generated, usually within 5-12 calendar days (7 days on average) of receipt of your sample in the laboratory.
Step 4: Results
Your clinician will receive the test report giving a clear indication of whether you are at risk of cancer or if you have already been diagnosed, what steps you – and possibly other members of your family – need to take next.
- Results►Close tab
Your clinician will be able to discuss your results and their implications for you, but as a guide:
A positive result does NOT mean you have cancer, or that you will definitely develop it.
It does means that a mutation, or genetic change, has been identified in a specific gene that increases the chance of your developing certain cancers in your lifetime – and your personal results will provide more detailed information specific to you. Talk to your clinician about creating a screening and management plan for you, and to identify relatives who may also need to be tested.
A negative result means that no mutations or genetic changes associated with an increased risk of the most common hereditary cancers were identified in the genes that were analysed. The result does not eliminate your risk of developing cancer completely as there are other factors, such as lifestyle, or perhaps mutations not detected by current technology or mutations in other genes. Again, talk to your clinician about what the results mean for you.
Variant of uncertain significance
This is where a gene mutation has been found, but at present we do not know if this affects your risk of certain cancers. In this case, your clinician will be able to talk about screening recommendations based on your personal and family medical histories and if new information becomes available, Invitae will update your clinician.
- Clinicians►Close tab
Is the Invitae BRCA1 and BRCA2 STAT panel right for your patient?
HBOC syndrome testing should be considered in individuals with a personal and/or family history of features, including:
- early onset breast cancer (age 50 or younger)
- triple negative (ER-, PR-, HER2-) breast cancer at age 60 or younger
- ovarian cancer
- male breast cancer
- multiple BRCA-associated cancers in the same person
- a family history of ovarian, breast, pancreatic, melanoma, or prostate cancer
- breast or ovarian cancer and Ashkenazi Jewish ethnicity
This test analyses the BRCA1 and BRCA2 genes, which are associated with hereditary breast and ovarian cancer syndrome (HBOC).
Accelerated turnaround time (TAT) may be necessary because physicians and patients often want to make surgical and management decisions as quickly as possible. Individuals with a pathogenic variant have a higher risk of developing another breast cancer and may choose more aggressive surgery and/or different treatment options based on genetic testing results. BRCA1 and BRCA2 have well established medical management guidelines.
This test is appropriate for breast cancer patients with upcoming cancer-related breast surgeries and/or treatment and genetic testing may inform decisions such as lumpectomy versus mastectomy, single versus double mastectomy, or use of other treatments (such as use of PARP inhibitors or other chemotherapy regimens). Identification of a disease-causing variant may also guide testing and management of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumour tissue.
Alternative tests to consider
HBOC can also be ordered as part of a broader panel. Depending on the individual’s clinical and family history, one of these broader panels may be appropriate. Any of these broader panels can be ordered at no additional charge.
- Invitae Breast Cancer STAT Panel
- Invitae Multi-Cancer Panel
- Validation►Close tab
- Easton, DF, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1993; 52(4):678-701. PMID: 8460634
- Ford, D, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998; 62(3):676-89. doi: 10.1086/301749. PMID: 9497246
- Antoniou, A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 2003; 72(5):1117-30. doi: 10.1086/375033. PMID: 12677558
- Hopper, JL, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol. Biomarkers Prev. 1999; 8(9):741-7. PMID: 10498392
- Hampel, H, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet. Med. 2015; 17(1):70-87. doi: 10.1038/gim.2014.147. PMID: 25394175
- Metcalfe, K, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 2004; 22(12):2328-35. doi: 10.1200/JCO.2004.04.033. PMID: 15197194
- Evans, DG, et al. Risk of breast cancer in male BRCA2 carriers. J. Med. Genet. 2010; 47(10):710-1. doi: 10.1136/jmg.2009.075176. PMID: 20587410
- Breast, Cancer, Linkage, Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 1999; 91(15):1310-6. doi: 10.1093/jnci/91.15.1310. PMID: 10433620
- Tai, YC, et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 2007; 99(23):1811-4. doi: 10.1093/jnci/djm203. PMID: 18042939
- Ford, D, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343(8899):692-5. doi: 10.1136/jmg.31.6.504-d. PMID: 7907678
- Petrucelli, N, et al. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 04. In: Pagon, RA, et al, editors. GeneReviews (Internet). University of Washington, Seattle; Available from: http://www.ncbi.nlm.nih.gov/books/NBK1247/ PMID: 20301425
- King, MC, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645):643-6. doi: 10.1126/science.1088759. PMID: 14576434
This test is provided by:
Frequently asked questions
- Do I need a doctor to authorise this test?
- Yes, your doctor will need to provide the sample required for this test.
- Will my health insurance cover the cost of this test?
- Many health insurance plans cover the cost of genetic testing – check with your provider to find out if it is in your policy.
- How accurate is the test?
- All our partners follow advanced laboratory procedures and ensure quality control to deliver accurate results you can trust.